Oncolys BioPharma Inc. (TYO:4588)

Market Cap	76.54B +448.0%
Revenue (ttm)	28.55M -9.0%
Net Income	-2.06B
EPS	-82.55
Shares Out	29.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	334,600
Open	2,663.00
Previous Close	2,613.00
Day's Range	2,610.00 - 2,738.00
52-Week Range	570.00 - 3,695.00
Beta	1.12
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Oncolys BioPharma

Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer. The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranucl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 44
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4588

Financial Performance

In 2024, Oncolys BioPharma's revenue was 31.38 million, a decrease of -50.21% compared to the previous year's 63.04 million. Losses were -1.68 billion, -13.09% less than in 2023.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 24, 2026

Data Sources Report a data error